___

• 1. Beydemir, Ş., Kulaçoğlu, D.N., Çiftçi, M., Küfrevioğlu, Ö.İ., The in vitro effects of dexamethasone on sheep lens glucose-6-phosphate dehydrogenase, Turk. J. Chem., 27, 601, 2003.
• 2. Ekinci, D., Beydemir, Ş., Alım, Z., Some drugs inhibit in vitro hydratase and esterase activities of human carbonic anhydrase-I and II, Pharmacol. Rep., 59, 580, 2007.
• 3. Aharoni, A., Gaidukov, L., Khersonsky, O., Gould, S.M., Roodveldt, C., The ‘evolvability’ of promiscuous protein functions, Nat. Genet., 37, 73, 2005.
• 4. Alici, H.A., Ekinci, D, Beydemir, Ş., Intravenous anesthetics inhibit human paraoxonase-I (PON1) activity in vitro and in vivo, Clin. Biochem., 41(16-17) 1384, 2008.
• 5. Khersonsky, O., Tawfik, D.S., Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase, Biochemistry-US., 44, 6371, 2005.
• 6. Rochua, D., Chabriere, E., Massona, P., Human paraoxonase: A promising approach for pre-treatment and therapy of organophosphorus poisoning, Toxicology, 233, 47, 2007.
• 7. Akgur, S.A., Ozturk, P., Solak, I., Moral, A.R., Human serum paraoxonase (PON1) activity in acute organophosphorus insecticide poisoning, Forensic Sci. Int., 133, 136, 2003.
• 8. Billecke, S., Draganov, D., Councell, R., Stetson, P., Watson, C., Hsu, C., La Du, B.N., Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters, Drug Metab. Dispos., 28, 1335, 2000.
• 9. Davies, H.G., Richter, R.J., Keifer, M., et al., The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin, Nat. Genet., 14, 334, 1996.
• 10. La Du, B.N., Human serum paraoxonase/arylesterase. In Pharmacogenetics of Drug Metabolism (Kalow, W., ed.), Pergamon Elmford, NY, pp: 51–91, 1992.
• 11. Abbott, C.A., Mackness, M.I., Kumar, S., Boulton, A.J., Durrington, P.N. Serum paraoxonase activity, concentration and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins, Arterioscl. Throm. Vas., 15, 1812, 1995.
• 12. Baskol, G., Demir, H., Baskol, M., Kilic, E., Ates, F., Kocer, D., Muhtaroglu, S. Assessment of Paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis, Clin. Biochem., 38, 951, 2005.
• 13. Baskol, G., Karakucuk, S., Oner, A.O., Baskol, M., Kocer, D., Mirza, E., Saraymen, R., Ustdal, M., Serum paraoxonase 1 activity and lipid peroxidation levels in patients with age-related macular degeneration, Ophthalmologica, 220, 12, 2006.
• 14. Dantoine, T.F., Debord, J., Charmes, J.P., Merle, L., Marquet, P., Lachatre, G., Leroux-Robert, C., Decrease of serum paraoxonase activity in chronic renal failure, J. Am. Soc. Nephrol., 9, 2082, 1998.
• 15. Raiszadeh, F., Solati, M., Etemadi, A., Rahmani, M., Arabi, M., Serum paraoxonase activity before and after treatment of thyrotoxicosis, Clin. Endocrinol., 60, 75, 2004.
• 16. Ames, B.N., Shigenaga, M.K., Hagen, T.M., Oxidants, antioxidant and the degenerative diseases of aging, Proc. Natl. Acad. Sci. USA, 90, 7915, 1993.
• 17. Harman, D., Aging: phenomena and theories, Ann. N.Y. Acad. Sci. USA, 854, 1, 1998.
• 18. Watson, A.D., Berliner, J.A., Hama, S.Y., La Du, B.N., Faull, K.F., Fogelman, A.M., Navab, M., Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein, J. Clin. Invest., 96, 2882, 1995.
• 19. Draganov, D.I., La Du, B., Pharmacogenetics of paraoxonases: a brief review, Naunyn. Schmiedebergs, Arch. Pharmacol., 369, 78, 2004.
• 20. Leviev, I., James, R., Simvastatin increases plasma levels of the antioxidant enzyme paraoxonase by PON1 gene activation, Atherosclerosis, 151, 41, 2000.
• 21. Malin, R., Laaksonen, R., Knuuti, J., Janatuinen, T., Vesalainen, R., Nuutila P., Lehtimäki, T., Paraoxonase genotype modifies the effect of pravastatin on highdensity lipoprotein cholesterol, Pharmacogenetics, 11, 625, 2001.
• 22. Tomás, M., Senti, M., Garcia-Faria, F., Vila, J., Torrents, A., Covas, M., Marrugat, J., Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients, Arterioscl. Throm. Vas., 20, 2113, 2000.
• 23. Beydemir, Ş., Gülçin, İ., Effects of melatonin on carbonic anhydrase from human erythrocyte in vitro and from rat erythrocyte in vivo, J. Enzym. Inhib. Med. Ch., 19, 193, 2004.
• 24. Lu, H.L., Chiang, C.H. Combined therapy of pentastarch, dexamethasone, and dibutyryl-cAMP or b2-agonist attenuates ischaemia/reperfusion injury of rat lung, Injury Int. J. Care. Injured, 39(9) 1062, 2008.
• 25. Petrellaa, A., Ercolinoa, S.F., Festaa, M., Gentilellaa, A., Toscoa, A., Conzenb, S.D., Parentea, L. Dexamethasone inhibits TRAIL-induced apoptosis of thyroid cancer cells via Bcl-xL induction, Eur. J. Cancer, 42(18) 3287, 2006.
• 26. Renault, F., Chabrière, E., Andrieu, J.P., Dublet, B., Masson, P., Rochu, D., Tandem purification of two HDLassociated partner proteins in human plasma, paraoxonase (PON1) and phosphate binding protein (HPBP) using hydroxyapatite chromatography, J. Chromatogr. B, 836, 15, 2006.
• 27. Sinan, S., Kockar, F., Arslan, O., Novel purification strategy for human PON1 and inhibition of the activity by cephalosporin and aminoglikozide derived antibiotics, Biochimie, 88, 565, 2006.
• 28. Yılmaz, H., Çiftçi, M., Beydemir, Ş., Bakan, E., Purification of glucose 6-phosphate dehydrogenase from chicken erythrocytes and investigation of some kinetic properties, Prep. Biochem. Biotech., 32, 287, 2002.
• 29. Bradford, M.M., A rapid and sensitive method for the quantition of microgram quantities of protein utilizing the principle of protein-dye binding, Anal. Biochem., 72, 248, 1976.
• 30. Laemmli, D.K., Cleavage of structural proteins during assembly of the head of bacteriophage T4, Nature, 227, 680, 1970.
• 31. Lineweaver, H., Burk, D., The determination of enzyme dissocation constants, J. Am. Chem. Soc., 57, 685, 1934.
• 32. Pla, A., Rodrigo, L., Hernandez, A.F., Gil, F., Lopez, O., Effect of metal ions and calcium on purified PON1 and PON3 from rat liver, Chem. Biol. Interact., 167, 63, 2007.
• 33. Abdollahi, M., Jalali, N., Jafari, A.A., Nikfar, S., A new approach to the efficacy of oximes in the management of acute organophosphate poisoning, Iran J. Med. Sci., 20, 105, 1995.
• 34. Shadnia, S., Azizi, E., Hosseini, R., Khoei, S., Fouladdel, S., Pajoumand, A., Jalali, N., Abdollahi, M., Evaluation of oxidative stres and genotoxicity in organophosphorus insecticide formulators, Hum. Exp. Toxicol., 9, 439, 2005.
• 35. Jaouad, L., Milochevitch, C., Khalil, A., PON1 paraoxonase activity is reduced during HDL oxidation and is an indicatr of HDL antioxidant capacity, Free Radic. Res., 37, 77, 2003.
• 36. Sorenson, R.C., Primo-Parmo, S.L., Kuo, C.L., Adkins, S., Lockridge, O., La Du, B.N., Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase, P. Natl. Acad. Sci. USA., 92, 7187, 1995.
• 37. Quéméneur, T., Martin-Nizard, F., Kandoussi, A., Kyndt, X., Vanhille, P., Hachulla, E., Hatron, P.Y., Fruchart, J.C., Duriez, P., Lambert, M., PON1, A new biomarker of cardiovascular disease, is low in patients with systemic vasculitis, Semin. Arthritis. Rheum., 37(3) 149, 2007.
• 38. Gülçin, I., Beydemir, Ş., Büyükokuroğlu, M.E., In vitro and in vivo effects of dantrolene on carbonic anhydrase enzyme activities, Biol. Pharm. Bull., 27, 613, 2004.
• 39. Furlong, C.E., Costa, L.G., Hasett, C., Richter, R.J., Sundstrom, J.A., Adler, D.A., Disteche, C.M., Omiecinski, C.J., Crabb, J.W., Humbert, R., Human and rabbit paraoxonases: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification, Chem. Biol. Interact., 87, 35, 1993.